Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), results from a retrospective study suggest. The study, “Right ventricular size and function under riociguat…

The discovery of a molecular factor that triggers blood clots in lung arteries may explain why chronic thromboembolic pulmonary hypertension (CTEPH) often occurs in patients without traditional clotting risk factors, according to a study. Researchers think the factor, called activated TAFI, could be used to identify those with CTEPH. And…

A team of researchers has published their results assessing left atrial volume in chronic thromboembolic pulmonary hypertension (CTEPH) patients before and after pulmonary thromboendarterectomy (PTE), a surgical procedure that removes organized, clotted blood from the pulmonary arteries. When the body cannot reabsorb a pulmonary embolism (PE), clots…

In people experiencing a pulmonary embolism, higher-than-normal arterial stiffness at the time of hospital discharge increased the risk of pulmonary arterial hypertension (PAH) when evaluated one month later, according to a study in Italy. Given that this patient population is at risk of chronic thromboembolic pulmonary hypertension…

Chronic thromboembolic pulmonary hypertension (CTEPH), a disease caused by unresolved pulmonary blood clots, is a major contributor to pulmonary hypertension. Previous reports have identified that…

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…

Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The risk profile was assessed using a risk score established to predict a response to treatment and survival in people with pulmonary arterial hypertension (PAH), the most common type…

According to the Cleveland Clinic, pulmonary hypertension (PH) is rare pulmonary disease. In PH patients, arteries become more narrow, making it difficult for blood to flow through the vessels between the heart and the lungs, increasing the blood pressure in the pulmonary arteries. MORE: The difficulties of diagnosing pulmonary arterial hypertension What causes…

Many people with chronic thromboembolic pulmonary hypertension or CTEPH have a particular anatomical variation called May-Thurner anatomy, which may increase the risk of developing this rare disease type, according to researchers. A new study found this anomaly is very common in individuals with CTEPH, with nearly 30% of patients…

Inhalation treatment that uses either nitric oxide or Ventavis (iloprost) is equally effective in managing lingering high lung blood pressure after surgery for chronic thromboembolic pulmonary hypertension (CTEPH). A comparison of the two treatments — published in the journal General Thoracic and Cardiovascular Surgery under the title, “A prospective, randomized study…

Approximately 5,000 Americans are diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) each year. The condition is a result of persistent obstruction of pulmonary blood vessels due to unresolved blood clots from previous episodes of acute pulmonary embolism. If patients do not receive treatment for CTEPH, they may develop…

A new survey sponsored by Bayer has revealed that many physicians report a lack of familiarity with a condition called chronic thromboembolic pulmonary hypertension (CTEPH). The 2015 Bayer PH Physician Survey was released on November 24 to help draw attention to CTEPH and the need for stepped-up education efforts to improve…